Study of an Evening Dose of Eszopiclone on Next Day Driving Ability & Psychomotor/Memory Function in Healthy Volunteers

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT00368160
Recruitment Status : Completed
First Posted : August 24, 2006
Last Update Posted : February 22, 2012
Information provided by (Responsible Party):

Brief Summary:
Male and female healthy volunteers. Patients must also possess a full current driving license (for at least one year), and be a regular car driver.

Condition or disease Intervention/treatment Phase
Insomnia Drug: Eszopiclone Drug: Placebo Phase 1

Detailed Description:
The study is a single centre, randomised, double blind, placebo controlled 2-way crossover design in a group of 32 healthy male and female volunteers. The medications under investigation are eszopiclone and placebo. Volunteers will receive the study medications and placebo on the evening of Day 2 of each treatment period. Performance will be assessed on Day 3 of each treatment period. Each treatment period will be separated by at least a 7-day washout period. This study was previously posted by Sepracor Inc. In October 2009, Sepracor Inc. was acquired by Dainippon Sumitomo Pharma., and in October 2010, Sepracor Inc's name was changed to Sunovion Pharmaceuticals Inc.

Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 32 participants
Allocation: Randomized
Intervention Model: Crossover Assignment
Masking: Triple (Participant, Investigator, Outcomes Assessor)
Primary Purpose: Treatment
Official Title: The Effects of a Single Evening Dose of 3 mg Eszopiclone on Next Day Driving Ability and Psychomotor/Memory Function in Healthy Volunteers Compared to Placebo
Study Start Date : March 2004
Actual Primary Completion Date : July 2005
Actual Study Completion Date : July 2005

Resource links provided by the National Library of Medicine

MedlinePlus related topics: Memory
Drug Information available for: Eszopiclone

Arm Intervention/treatment
Experimental: 1
eszopiclone 3 mg
Drug: Eszopiclone
eszopiclone 3 mg
Other Names:
  • S-Zopiclone
  • Lunesta

Placebo Comparator: 2
Placebo tablet
Drug: Placebo
Placebo tablet

Primary Outcome Measures :
  1. next day performance in a standardised test of car driving [ Time Frame: 9.5 hours post dose ]

Secondary Outcome Measures :
  1. Compensatory Tracking Task (CTT) [ Time Frame: 9.5 hours post dose ]
  2. Rapid Visual Information Processing (RVIP) [ Time Frame: 9.5 hours post dose ]
  3. Sternberg's Short-term Memory Scanning task (STM) [ Time Frame: 9.5 hours post dose ]
  4. Critical Flicker Fusion (CFF) [ Time Frame: 9.5 hours post dose ]
  5. Digit Symbol Substitution Test (DSST) [ Time Frame: 9.5 hours post dose ]
  6. Choice Reaction Time (CRT) [ Time Frame: 9.5 hours post dose ]
  7. Leeds Sleep Evaluation Questionnaire and Leeds Analogue Rating Scales [ Time Frame: 9.5 hours post dose ]

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Ages Eligible for Study:   18 Years to 55 Years   (Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   Yes

Inclusion Criteria:

  • Aged between 18 and 55 years inclusive
  • In good health as determined by a medical history, ECG, haematology, blood and urine biochemistry and physical examination by the doctor
  • A body mass index greater than or equal to 18 and less than or equal to 30
  • Registered with a general practitioner (GP)
  • Hold a full current driving licence for at least one year, and be regular car drivers

Exclusion Criteria

  • Clinically significant use of psychotropic medication in the last three months. For example, this would include the prolonged use of antidepressants, antipsychotics, or antihistamines, but would exclude the occasional use of cold or flu remedies (which often contain antihistamines and/ or opiates)
  • The use of any other medication in the last two weeks with the exception of oral, transdermal, IUDs (progestogen only contraceptive e.g. Mirena), or depot contraceptives, non-steroidal analgesics (e.g. ibuprofen), and paracetamol
  • Significant history of mental illness, significant drug allergy, malignancy or chronic drug abuse (including alcohol)
  • Any subject with known hypersensitivity to any of the study treatments
  • A sleep/ wake cycle (e.g. shift work) liable to prejudice the results of the study
  • Pregnant or lactating females, and females of child bearing potential not using effective contraception
  • Volunteers who habitually smoke more than 5 cigarettes per day
  • Caffeine consumption of more than 5 cups or glasses per day
  • History of alcohol or drug dependence or intake of more than the equivalent of 14 units of alcohol per week for females and 21 units per week for males
  • Current participation in another clinical trial, or participation in a clinical trial within the last 90 days

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT00368160

United Kingdom
HPRU Medical Research Centre
Guildford, Surrey, United Kingdom
Sponsors and Collaborators

Responsible Party: Sunovion Identifier: NCT00368160     History of Changes
Other Study ID Numbers: 190-059
First Posted: August 24, 2006    Key Record Dates
Last Update Posted: February 22, 2012
Last Verified: February 2012

Keywords provided by Sunovion:
Next day driving

Additional relevant MeSH terms:
Hypnotics and Sedatives
Central Nervous System Depressants
Physiological Effects of Drugs